# A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance

> **NCT05923281** · PHASE3 · COMPLETED · sponsor: **Kowa Company, Ltd.** · enrollment: 71 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** K-877 0.2 mg/day (once daily)
- **DRUG:** K-877 0.4 mg/day (once daily)
- **DRUG:** Placebo (once daily)

## Key facts

- **NCT ID:** NCT05923281
- **Lead sponsor:** Kowa Company, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-01
- **Primary completion:** 2024-08-07
- **Final completion:** 2024-08-07
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923281, "A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05923281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*